Ethical aspects
This was an experimental study conducted at the Federal University of Ouro Preto, approved by the Human Research Ethics Committee under protocol no. 25402813.2.1001.5150. To participate in the study, the participants were made aware of the study objectives and the possible benefits and risks. All provided informed written consent.
Patient characteristics
A sample of twenty-one cyclists of both sexes volunteered for this study. Average age was 29 ± 5 years; Average body weight was 71 ± 7 kg; Average height was 1.70 ± 0.07 m; Average body mass index was 24 ± 2 kg/m2. The inclusion criteria were involvement in training programs for at least 12 months and completion of at least four sessions of MTB training per week.
Participants were excluded if they had used supplements with potential effects on physical performance, had current injuries or in the last six months, were not willing to abstain from intense exercise 24 hours before the test. Participants were tested at the same time of day for each one of the experimental visits.
Figure 1 - Participants recruitment flow diagram.
Experimental Design
The distribution of the supplement was double-blinded and randomized. Participants received either the formulation of HPβ-CD-Placebo or the HPβ-CD-Ang-(1-7) (1.75 mg), ensuring that 50% of subjects randomly used HPβ-CD-Placebo in the first session and HPβ-CD-Ang-(1-7) in the second session or vice versa. The double-blinding and randomization of the experiments was made by a third person who was not involved in data collection. The groups were revealed to other researchers only at the time of data interpretation.
A single dose of the HPβ-CD-Placebo or formulation HPβ-CD-Ang-(1-7) was given orally, both in capsule form, three hours before the beginning of each test. The capsules were identical in color, size and without flavor, ensuring the blinding of the participants.
During the intervention, we requested that physical training, food intake, and sleep hours be maintained. The volunteers were subjected to two days of tests with a seven-day interval between them, which can be considered a safe washout time. Upon return to the laboratory, we took histories from the subjects to determine if there were adverse reactions and if they had maintained their diet and physical training routines.
Figure 2 - Experimental trial schematic.
Physical exercise protocol using the leg ergometer cycle
The test protocol was based on previous studies with MTB athletes 12. The tests were performed usinga leg ergometer cycle (Biotec 2100, CEFISE Biotechnology), with 10 minutes of warm up and a load of 12.5 W for both genders. After warming up, a continuous progressive load test was performed with an initial load of 25W for women and 37.5W for men. The load was increased by 12.5 W every three minutes for both genders. The test finished when the individual reached voluntary exhaustion or when the rotation could not be kept at 70 rpm. At the end of each stage, heart rate (HR), ratings of perceived exertion (RPE), maximal oxygen uptake (VO2), and respiratory exchange coefficient (REC) were collected.
Supplementation protocol
The formulation was developed by the Laboratory of Hypertension and Laboratory of Chemical of the University of Federal of Minas Gerais; the details were described previously 13. This compound (HPβCD/Ang-(1-7)) was patented (BR 10 2016 0244064).
Oral supplementation with HPβCD-angiotensin-(1-7) (1.75mg) or HPβCD-placebo (1.75mg) was administered 3 hours before the test protocol. The 3h time was pre-established considering the peak action of angiotensin-(1-7) which has a window ofaction between 2 to 6 hours 14.
Considering toxicity and adverse responses in humans, the present study used a dose 16 times lower than the dose used in a study conducted in cancer patients (400 μg/kg)15 that showed no collateral effects. In addition, a previous study in healthy younger 11 showed protective effects against muscle damage using the same dose without side-effects.
Plasma analysis
Blood samples were collected from the antecubital vein by a skilled phlebotomist using standard technical venipuncture. Approximately 12 ml were collected in vacutainer tubes containing heparin. Immediately after collection, the blood was centrifuged at 3.000 rpm for ten minutes, and the serum transferred to Eppendorf tubes stored at –80 °C. Aliquots were used to measure non-esterified fatty acids (NEFA) and creatine kinase (CK).
Blood lactate levels
Lactate levels were measured in each participant's index finger by placing one drop (5 μl) of blood on a BM-Lactate reagent strip (Roche Diagnostics GmbH, D68298 Mannheim, Germany) and introducing it into the Accutrend® Lactate meter (Roche Diagnostics GmbH, D-68298 Mannheim, Germany). Lactate was measured immediately at the end of each test.
Non-esterified fatty acids (NEFAs)
NEFAs were analyzed according to the specific colorimetric method using the Randox® kit (Randox Laboratories, Oceanside, CA, USA).
Mechanical work and efficiency
To calculate mechanical work and efficiency, the equations above were used 16. Work is described as follows: w = time (min) × load (kg) × wheel circumference (m) × rotation (rpm), in kg.m., while mechanical efficiency was calculated using the equation:
where the perfect machine constant is the energy spent by a machine without loss of efficiency to perform work (1 kcal = 426.4 kg.m) in %.
Evaluation of BP and HR
Blood pressure was measured using an aneroid sphygmomanometer (Missouri®, Brasil) and a stethoscope (Missouri®, Brasil) before and soon after completion of the test protocol. HR was measured using the Polar RS800 (POLAR, Finland) at rest, throughout the stages, and at the maximum effort peak of the physical test.
Evaluation of subjective rating of perceived exertion (RPE)
Participants evaluated their fatigue using the subjective rating of perceived exertion with reference to the Borg Scale 17. RPE was determined at each stage completed by the volunteer.
Evaluation of maximum oxygen consumption
The aerobic capacity was determined in the HPβ-CD-placebo and HPβ-CD-Ang-(1-7) conditions using open-circuit spirometry on VO2000® (VO2000, MedGraphics®️, Saint Paul, Minessota-USA) equipment during the leg ergometer cycle physical test calibrated before each test. The ventilatory equivalent for oxygen (VE/VO2), ventilatory equivalent for carbon dioxide (VE/VCO2), and respiratory exchange ratio (RER) were recorded at each stage completed to determine maximal oxygen uptake and respiratory exchange quotient. The average of the final two minutes of the test was used to determine the relative VO2 18.
Statistical analysis
Data normality was tested using the D'Agostino & Pearson test. The data that were normally distributed were compared using the paired t-test. For non normal data, the Wilcoxon matched pairs signed rank test was used. Information regarding data normality was added to the figures. Data were expressed as mean ± standard deviation (SD) and the significance level was p <0.05 for all tests. For the evaluation throughout the stages of the physical test, a regression using equations of straight line were also used. To run the test, we chose the fitting method of least squares regression without weighting. The null hypothesis was that one curve would fit the two conditions (HPβ-CD-Placebo and HPβ-CD-Ang-(1-7). The curve comparison method was the extra sum-of-squares F-test and the p-value was fixed at 0.05. The measurement of effect size used was Cohen’s d (Cohen's d = (M2 - M1) ⁄SDpooled). The effect size was evaluated based on Cohen’s guidelines: small (0.2), medium (0.5), and large (0.8). The lower 95% CI of the mean and the upper 95% CI of the mean for both groups were added to the figure legend.